EXPLORING NEW MEDICAL HORIZONS
It took a long time – far too long, but better late than never – for U.S. regulators to catch up with science in the area of behavioral medicine. That’s not unusual because governments tend to be inefficient, but the Food and Drug Administration couldn’t deny what’s been proven by rigorous scientific research.
For patients who suffer from chronic depression, anxiety, and other mood disorders, the medications they get from their doctors often fail to effectively treat the symptoms. In other cases, they’re dangerously addictive. Sometimes, they could have unmanageable side effects or can drastically change the patient’s personality or behavior.
Instead of having to deal with all of that, imagine having access to a treatment that’s quicker and potentially more effective without so many unwanted side effects. This is a reality, and it’s happening today thanks to scientific breakthroughs by a small but growing community of researchers.
In recent years, clinics have experimented with the intravenous delivery of ketamine, a psychedelic agent that’s currently being researched for its ability to treat a range of mental health conditions including depression, anxiety, and post-traumatic stress disorder (PTSD).
Ketamine got a bad rap years ago because it had been used illegally as a so-called “party drug,” but it recently earned legitimacy in March of 2019 when the Food and Drug Administration approved a nasal-spray version of ketamine. This was a landmark decision and a godsend to the estimated five million Americans who suffer from depression that hasn’t responded to other treatments.
The research findings are already highly encouraging, with ketamine found to treat depression faster than traditional antidepressants. And while Prozac typically takes weeks or months before suicidal patients can manage their urge to self-harm, ketamine was found to quell potentially suicidal thoughts within 24 to 48 hours.
This is great news for the millions of people around the world who suffer from depression and other mood disorders, but the cycle wouldn’t be complete unless a company could step up and deliver safe, effective ketamine products to the public quickly and reliably.
The company at the forefront of this scientific movement to deliver better behavioral health treatments is Champignon Brands (CSE: SHRM, OTC: SHRMF), a emerging leader in providing novel solutions through the development and commercialization of rapid-onset, psychedelic-based treatments.
93% Of Investors Generate Annual Returns, Which Barely Beat Inflation.
Wealth Education and Investment Principles Are Hidden From Public Database On Purpose!
Build The Knowledge Base To Set Yourself Up For A Wealthy Retirement and Leverage The Relationships We Are Forming With Proven Small-Cap Management Teams To Hit Grand-Slams!
Champignon’s flagship clinic is licensed to administer ketamine treatments for indications, including, but not limited to, depression, bipolar disorder, posttraumatic stress disorder and obsessive-compulsive disorder (OCD). The company’s clinic is the only vertically integrated rapid-onset treatment centre operating from proof of concept to human clinical trials and publication, with study results in peer-reviewed journals by the world’s leading experts in psychopharmacology.
The company stands ready to, among other things, open a minimum of five new clinics in key markets, including New York, Florida and California, which are anticipated to be fully operational by Q4 2020.
With regulators relaxing their rules and Champignon making great strides in developing the market, there’s no limit to how far ketamine-enhanced therapies could go in treating behavioral issues better, faster, and less problematically than any traditional medication ever has.
Governments Have Amassed ungodly Debt Piles and Have Promised Retirees Unreasonable Amounts of Entitlements, Not In Line with Income Tax Collections. The House of Cards Is Set To Be Worse than 2008! Rising Interest Rates Can Topple The Fiat Monetary Structure, Leaving Investors with Less Than Half of Their Equity Intact!
Protect Yourself Now, By Building A Fully-Hedged Financial Fortress!
This work is based on SEC filings, current events, interviews, corporate press releases and what we’ve learned as financial journalists. It may contain errors and you shouldn’t make any investment decision based solely on what you read here. It’s your money and your responsibility. The information herein is not intended to be personal legal or investment advice and may not be appropriate or applicable for all readers. If personal advice is needed, the services of a qualified legal, investment or tax professional should be sought.
Never base any decision off of our emails. FutureMoneyTrends.com stock profiles are intended to be stock ideas, NOT recommendations. The ideas we present are high risk and you can lose your entire investment, we are not stock pickers, market timers, investment advisers, and you should not base any investment decision off our website, emails, videos, or anything we publish. Please do your own research before investing. It is crucial that you at least look at current SEC filings and read the latest press releases. Information contained in this profile was extracted from current documents filed with the SEC, the company web site and other publicly available sources deemed reliable. Never base any investment decision from information contained in our website or emails or any or our publications. You should know that Gold Standard Media LLC, owned by the same parties as Future Money Trends LLC, has been compensated three hundred thousand dollars, directly by the company, for a two year public awareness campaign. Our report is not intended to be, nor should it be construed as an offer to buy or sell, or a solicitation of an offer to buy or sell securities, or as a recommendation to purchase anything. This publication may provide the addresses or contain hyperlinks to websites; we disclaim any responsibility for the content of any such other websites. Please use our site as a place to get ideas. Enjoy our videos and news analysis, but never make an investment decision off of anything we say.